See more : Archidply Industries Limited (ARCHIDPLY.BO) Income Statement Analysis – Financial Results
Complete financial analysis of Codexis, Inc. (CDXS) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Codexis, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Nakakita Seisakusho Co., Ltd. (6496.T) Income Statement Analysis – Financial Results
- Castex Technologies Limited (CASTEXTECH.NS) Income Statement Analysis – Financial Results
- Mazagon Dock Shipbuilders Limited (MAZDOCK.NS) Income Statement Analysis – Financial Results
- Mydas Real Estate Investments Ltd (MYDS.TA) Income Statement Analysis – Financial Results
- China Railway Signal & Communication Corporation Limited (3969.HK) Income Statement Analysis – Financial Results
Codexis, Inc. (CDXS)
About Codexis, Inc.
Codexis, Inc. discovers, develops, and sells enzymes and other proteins. It offers biocatalyst products and services; intermediate chemicals products that are used for further chemical processing; and Codex biocatalyst panels and kits that enable customers to perform chemistry screening. The company also provides biocatalyst screening and protein engineering services. In addition, it offers CodeEvolver protein engineering technology platform, which helps in developing and delivering biocatalysts that perform chemical transformations and enhance the efficiency and productivity of manufacturing processes. The company's platform is also used to discover novel biotherapeutic drug candidates for targeted human diseases, as well as for molecular biology and in vitro diagnostic enzymes. It sells its products to pharmaceutical manufacturers through its direct sales and business development force in the United States and Europe. The company was incorporated in 2002 and is headquartered in Redwood City, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 70.14M | 138.59M | 104.75M | 69.06M | 68.46M | 60.59M | 50.02M | 48.84M | 41.80M | 35.31M | 31.92M | 88.30M | 123.87M | 107.10M | 82.91M | 50.48M | 25.33M | 12.13M |
| Cost of Revenue | 12.81M | 38.03M | 22.21M | 13.74M | 15.63M | 12.62M | 14.33M | 9.75M | 6.59M | 9.73M | 14.55M | 30.65M | 41.78M | 27.98M | 16.68M | 13.19M | 8.32M | 1.81M |
| Gross Profit | 57.33M | 100.56M | 82.55M | 55.31M | 52.83M | 47.97M | 35.70M | 39.08M | 35.22M | 25.58M | 17.37M | 57.65M | 82.08M | 79.12M | 66.23M | 37.29M | 17.01M | 10.32M |
| Gross Profit Ratio | 81.74% | 72.56% | 78.80% | 80.10% | 77.17% | 79.17% | 71.36% | 80.03% | 84.25% | 72.45% | 54.41% | 65.29% | 66.27% | 73.87% | 79.88% | 73.87% | 67.16% | 85.11% |
| Research & Development | 58.89M | 80.10M | 55.92M | 44.19M | 33.87M | 29.98M | 29.66M | 22.23M | 20.67M | 22.76M | 31.61M | 56.79M | 61.05M | 52.41M | 54.73M | 45.55M | 35.64M | 17.26M |
| General & Administrative | 52.95M | 51.87M | 49.02M | 34.75M | 31.00M | 28.79M | 28.31M | 24.92M | 22.02M | 21.64M | 26.41M | 30.98M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 300.00K | 300.00K | 300.00K | 300.00K | 500.00K | 500.00K | 700.00K | 500.00K | 300.00K | 300.00K | 500.00K | 400.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 53.25M | 52.17M | 49.32M | 35.05M | 31.50M | 29.29M | 29.01M | 25.42M | 22.32M | 21.94M | 26.91M | 31.38M | 36.94M | 33.84M | 29.87M | 35.71M | 19.71M | 11.88M |
| Other Expenses | 13.27M | 124.00K | 1.15M | -156.00K | -656.00K | -291.00K | -92.00K | -94.00K | -168.00K | -234.00K | 24.74M | -326.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 125.40M | 132.27M | 105.24M | 79.23M | 65.38M | 59.27M | 58.67M | 47.65M | 42.99M | 44.69M | 58.51M | 88.16M | 97.99M | 86.25M | 84.60M | 81.26M | 55.36M | 29.14M |
| Cost & Expenses | 138.21M | 170.30M | 127.45M | 92.98M | 81.01M | 71.89M | 72.99M | 57.40M | 49.57M | 54.42M | 73.07M | 118.81M | 139.77M | 114.23M | 101.27M | 94.45M | 63.68M | 30.94M |
| Interest Income | 4.17M | 1.44M | 459.00K | 405.00K | 1.29M | 671.00K | 147.00K | 60.00K | 19.00K | 18.00K | 60.00K | 252.00K | 273.00K | 166.00K | 180.00K | 1.54M | 1.49M | 742.00K |
| Interest Expense | 0.00 | 1.44M | 0.00 | 0.00 | 0.00 | 671.00K | 147.00K | 60.00K | 19.00K | 18.00K | 304.00K | 274.00K | 675.00K | 1.20M | 2.04M | 2.37M | 2.53M | 724.00K |
| Depreciation & Amortization | 9.92M | 10.25M | 5.95M | 4.55M | 4.77M | 1.15M | 1.04M | 4.55M | 5.41M | 6.69M | 10.32M | 12.42M | 11.47M | 8.31M | 6.13M | 4.56M | 2.88M | 2.39M |
| EBITDA | -49.28M | -23.07M | -16.75M | -19.37M | -7.99M | -10.15M | -21.93M | -4.02M | -2.36M | -12.64M | -31.07M | -18.17M | -4.84M | 681.00K | -12.06M | -37.87M | -35.67M | -15.69M |
| EBITDA Ratio | -70.26% | -20.60% | -21.67% | -34.64% | -18.33% | -18.64% | -45.92% | -17.54% | -18.59% | -54.13% | -128.71% | -34.56% | -3.36% | 1.26% | -14.54% | -75.03% | -134.09% | -129.36% |
| Operating Income | -68.07M | -31.71M | -22.70M | -23.92M | -12.55M | -11.30M | -22.97M | -8.56M | -7.77M | -19.11M | -41.15M | -30.51M | -15.91M | -7.12M | -18.37M | -43.97M | -38.34M | -18.82M |
| Operating Income Ratio | -97.04% | -22.88% | -21.67% | -34.64% | -18.33% | -18.64% | -45.92% | -17.54% | -18.59% | -54.13% | -128.90% | -34.56% | -12.84% | -6.65% | -22.15% | -87.11% | -151.36% | -155.16% |
| Total Other Income/Expenses | -8.10M | 1.57M | 1.61M | 249.00K | 631.00K | 380.00K | 55.00K | -34.00K | -149.00K | -216.00K | -244.00K | -74.00K | -402.00K | -1.03M | -1.86M | -827.00K | -1.04M | 18.00K |
| Income Before Tax | -76.17M | -33.32M | -21.09M | -23.67M | -11.92M | -10.92M | -22.92M | -8.60M | -7.92M | -19.33M | -41.39M | -30.59M | -16.31M | -8.16M | -20.22M | -44.80M | -39.39M | -18.80M |
| Income Before Tax Ratio | -108.59% | -24.04% | -20.13% | -34.28% | -17.41% | -18.01% | -45.81% | -17.61% | -18.94% | -54.74% | -129.66% | -34.64% | -13.17% | -7.62% | -24.39% | -88.75% | -155.47% | -155.01% |
| Income Tax Expense | 69.00K | 276.00K | 189.00K | 339.00K | 17.00K | -37.00K | 81.00K | -40.00K | -338.00K | -256.00K | -87.00K | 270.00K | 241.00K | 384.00K | 66.00K | 327.00K | -408.00K | -127.00K |
| Net Income | -76.24M | -33.59M | -21.28M | -24.01M | -11.94M | -10.88M | -23.00M | -8.56M | -7.58M | -19.07M | -41.30M | -30.86M | -16.55M | -8.54M | -20.29M | -45.13M | -38.98M | -18.67M |
| Net Income Ratio | -108.69% | -24.24% | -20.31% | -34.77% | -17.43% | -17.95% | -45.97% | -17.52% | -18.13% | -54.01% | -129.39% | -34.95% | -13.36% | -7.97% | -24.47% | -89.40% | -153.86% | -153.96% |
| EPS | -1.12 | -0.51 | -0.33 | -0.40 | -0.21 | -0.21 | -0.50 | -0.21 | -0.19 | -0.50 | -1.08 | -0.84 | -0.46 | -0.35 | -7.74 | -16.63 | -14.36 | -6.88 |
| EPS Diluted | -1.12 | -0.51 | -0.33 | -0.40 | -0.21 | -0.21 | -0.50 | -0.21 | -0.19 | -0.50 | -1.08 | -0.84 | -0.46 | -0.35 | -7.74 | -16.63 | -14.36 | -6.88 |
| Weighted Avg Shares Out | 68.13M | 65.34M | 64.57M | 59.36M | 56.53M | 52.21M | 46.23M | 40.63M | 39.44M | 38.21M | 38.23M | 36.77M | 35.67M | 24.59M | 2.62M | 2.71M | 2.71M | 2.71M |
| Weighted Avg Shares Out (Dil) | 68.13M | 65.34M | 64.57M | 59.36M | 56.53M | 52.21M | 46.23M | 40.63M | 39.44M | 38.21M | 38.23M | 36.77M | 35.67M | 24.59M | 2.62M | 2.71M | 2.71M | 2.71M |
Codexis: A Company Rooting Itself In A Blossoming Market
Codexis is a protein engineering company based in the United States that markets its products globally. The protein engineering industry is experiencing rapid growth as increased investment signals great potential for companies operating in the market.
Codexis, Inc. (CDXS) CEO John Nicols on Q4 2021 Results - Earnings Call Transcript
Codexis, Inc. (CDXS) CEO John Nicols on Q4 2021 Results - Earnings Call Transcript
Codexis (CDXS) Reports Q4 Loss, Tops Revenue Estimates
Codexis (CDXS) delivered earnings and revenue surprises of 11.11% and 1.73%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Codexis (CDXS) Surges 6.2%: Is This an Indication of Further Gains?
Codexis (CDXS) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
What Makes Codexis (CDXS) a New Strong Buy Stock
Codexis (CDXS) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Week 52 MDA Breakout Stocks - December 2021: Short-Term Picks To Give You An Edge
Two sample Breakout Stocks for Week 52 with better than 10% short-term upside potential and a Dow stock pick. This past week, two stocks beat 10% peak gains in FLGT +19.1% and DYAI +13.8% with Momentum Gauge® values improving through...
3 Synthetic Biology Stocks in Focus With Strong Potential
Here we discuss three stocks - CDXS, PGEN, VERV - engaged in the field of scientific biology that investors may keep a tab of as these have the potential to generate wealth for them going forward.
Codexis (CDXS) Q3 Earnings and Revenues Beat Estimates
Codexis (CDXS) delivered earnings and revenue surprises of 133.33% and 27.85%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Codexis' (CDXS) CEO John Nicols on Q3 2021 Results - Earnings Call Transcript
Codexis' (CDXS) CEO John Nicols on Q3 2021 Results - Earnings Call Transcript
Codexis to Report Third Quarter 2021 Financial Results on November 4
REDWOOD CITY, Calif., Oct. 21, 2021 (GLOBE NEWSWIRE) -- Codexis, Inc. (Nasdaq:CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, today announced that it will report its financial results for the third quarter of 2021 on Thursday,...
Source: https://incomestatements.info
Category: Stock Reports